THURSDAY, Nov. 3, 2022 (HealthDay News) — The prevalence of benign prostatic hyperplasia is increasing globally, according to a study published online Oct. 20 in The Lancet Healthy Longevity.

Atalel Fentahun Awedew, M.D., from Addis Ababa University in Ethiopia, and colleagues estimated global trends in, and prevalence of, benign prostatic hyperplasia and disability-adjusted life-years (DALYs) due to benign prostatic hyperplasia in 21 regions and 204 countries and territories from 2000 to 2019.

The researchers identified 94.0 million prevalent cases of benign prostatic hyperplasia globally in 2019 compared with 51.1 million in 2000, with an age-standardized prevalence of 2,480 per 100,000 people. There was a 70.5 percent increase in the global number of prevalent cases between 2000 and 2019, but the global age-standardized prevalence remained stable (−0.770 percent). In 2019, the age-standardized prevalence varied from 6,480 to 987 per 100,000 in Eastern Europe and in North Africa and the Middle East, respectively. There was an increase observed in the absolute DALY burden between 2000 and 2019 in all five sociodemographic index (SDI) quintiles. The middle, low-middle, and low SDI quintiles had the most rapid increases in the absolute DALY burden (94.7, 77.3, and 77.7 percent, respectively). Age-standardized DALY rates changed less between 2000 and 2019, but the three lower SDI quintiles saw small increases.

“The burden of benign prostatic hyperplasia is rising throughout the world, primarily due to population growth and ageing,” the authors write. “Consequently, the male burden on the existing health care system is expected to grow substantially in the coming year.”

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text


Copyright © 2022 HealthDay. All rights reserved.